Cargando…

HIV medication-based urolithiasis

Drug-induced renal calculi represent 1–2% of all renal calculi. In the last decade, drugs used for the treatment of HIV-infected patients have become the most frequent cause of drug-containing urinary calculi. Among these agents, protease inhibitors (PIs) are well known to induce kidney stones, espe...

Descripción completa

Detalles Bibliográficos
Autores principales: Izzedine, Hassane, Lescure, François Xavier, Bonnet, Fabrice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377784/
https://www.ncbi.nlm.nih.gov/pubmed/25852859
http://dx.doi.org/10.1093/ckj/sfu008
_version_ 1782363958388195328
author Izzedine, Hassane
Lescure, François Xavier
Bonnet, Fabrice
author_facet Izzedine, Hassane
Lescure, François Xavier
Bonnet, Fabrice
author_sort Izzedine, Hassane
collection PubMed
description Drug-induced renal calculi represent 1–2% of all renal calculi. In the last decade, drugs used for the treatment of HIV-infected patients have become the most frequent cause of drug-containing urinary calculi. Among these agents, protease inhibitors (PIs) are well known to induce kidney stones, especially indinavir and atazanavir, and more recently darunavir. Urolithiasis attributable to other PIs has also been reported in clinical cases such as those during non-PI use. Antiretroviral drug-induced calculi deserve consideration because most of them are potentially preventable. This article summarizes the diagnosis, epidemiology, prevention and management of antiretroviral drug-induced urolithiasis.
format Online
Article
Text
id pubmed-4377784
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-43777842015-04-07 HIV medication-based urolithiasis Izzedine, Hassane Lescure, François Xavier Bonnet, Fabrice Clin Kidney J Original Contributions Drug-induced renal calculi represent 1–2% of all renal calculi. In the last decade, drugs used for the treatment of HIV-infected patients have become the most frequent cause of drug-containing urinary calculi. Among these agents, protease inhibitors (PIs) are well known to induce kidney stones, especially indinavir and atazanavir, and more recently darunavir. Urolithiasis attributable to other PIs has also been reported in clinical cases such as those during non-PI use. Antiretroviral drug-induced calculi deserve consideration because most of them are potentially preventable. This article summarizes the diagnosis, epidemiology, prevention and management of antiretroviral drug-induced urolithiasis. Oxford University Press 2014-04 2014-03-11 /pmc/articles/PMC4377784/ /pubmed/25852859 http://dx.doi.org/10.1093/ckj/sfu008 Text en © The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please email: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Contributions
Izzedine, Hassane
Lescure, François Xavier
Bonnet, Fabrice
HIV medication-based urolithiasis
title HIV medication-based urolithiasis
title_full HIV medication-based urolithiasis
title_fullStr HIV medication-based urolithiasis
title_full_unstemmed HIV medication-based urolithiasis
title_short HIV medication-based urolithiasis
title_sort hiv medication-based urolithiasis
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377784/
https://www.ncbi.nlm.nih.gov/pubmed/25852859
http://dx.doi.org/10.1093/ckj/sfu008
work_keys_str_mv AT izzedinehassane hivmedicationbasedurolithiasis
AT lescurefrancoisxavier hivmedicationbasedurolithiasis
AT bonnetfabrice hivmedicationbasedurolithiasis